Matti S. Aapro

Matti S. Aapro, MD, FRCR (Hon) is Founder and Emeritus Medical Director of the Genolier Cancer Centre in Switzerland and one of the world's most recognized authorities on supportive care in oncology, particularly chemotherapy-induced nausea and vomiting (CINV). As a longtime president and scientific leader of the Multinational Association of Supportive Care in Cancer (MASCC), Dr. Aapro has been the principal architect of the MASCC/ESMO antiemetic guidelines, which are adopted by oncology programs worldwide. He contributed to the clinical development of multiple antiemetic agents including NK1 receptor antagonists (aprepitant, netupitant) and second-generation 5-HT3 antagonists (palonosetron), and has led numerous randomized trials and systematic reviews establishing optimal prophylactic antiemetic regimens for highly and moderately emetogenic chemotherapy. Dr. Aapro has also made seminal contributions to the management of myelosuppression, anemia of cancer, and febrile neutropenia. He has published over 500 peer-reviewed papers and book chapters and has received honorary degrees and fellowships from institutions across Europe and North America.